Free Trial

PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

$69.35
+1.02 (+1.49%)
(As of 07/12/2024 ET)
Today's Range
$67.66
$70.52
50-Day Range
$58.09
$69.35
52-Week Range
$24.83
$77.00
Volume
698,206 shs
Average Volume
483,396 shs
Market Capitalization
$3.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.20

PROCEPT BioRobotics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11.8% Downside
$61.20 Price Target
Short Interest
Bearish
10.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.58mentions of PROCEPT BioRobotics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5.52 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.93) to ($1.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.62 out of 5 stars

Medical Sector

852nd out of 917 stocks

Surgical & Medical Instruments Industry

95th out of 101 stocks

PRCT stock logo

About PROCEPT BioRobotics Stock (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

PRCT Stock Price History

PRCT Stock News Headlines

Billionaire opens new pathway to wealth for investors
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Billionaire opens new pathway to wealth for investors
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
See More Headlines
Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
7/13/2024
Next Earnings (Estimated)
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PRCT
Fax
N/A
Employees
430
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.20
High Stock Price Target
$75.00
Low Stock Price Target
$37.00
Potential Upside/Downside
-11.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-105,900,000.00
Pretax Margin
-66.12%

Debt

Sales & Book Value

Annual Sales
$136.19 million
Book Value
$5.56 per share

Miscellaneous

Free Float
42,476,000
Market Cap
$3.57 billion
Optionable
Optionable
Beta
1.00
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 69)
    President, CEO & Director
    Comp: $1.13M
  • Mr. Kevin Waters (Age 47)
    Executive VP & CFO
    Comp: $680.11k
  • Ms. Alaleh Nouri (Age 45)
    EVP, Chief Legal Officer & Corporate Secretary
    Comp: $605.84k
  • Mr. Hisham Shiblaq (Age 48)
    Executive VP & Chief Commercial Officer
    Comp: $645.95k
  • Mr. Mohan F. Sancheti (Age 60)
    Senior Vice President of Operations
  • Mr. Barry Templin
    Executive VP of Technology & Clinical Development
  • Mr. Matthew James Bacso C.F.A.
    Vice President of Investor Relations
  • Ms. Stacey L. Porter (Age 48)
    Chief People Officer
  • Mr. Bijesh Chandran
    Senior Vice President of Regulatory Affairs & Quality Assurance

PRCT Stock Analysis - Frequently Asked Questions

How have PRCT shares performed this year?

PROCEPT BioRobotics' stock was trading at $41.91 on January 1st, 2024. Since then, PRCT shares have increased by 65.5% and is now trading at $69.35.
View the best growth stocks for 2024 here
.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.04. The company's revenue was up 82.4% compared to the same quarter last year.

When did PROCEPT BioRobotics IPO?

PROCEPT BioRobotics (PRCT) raised $126 million in an IPO on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' top institutional investors include Contravisory Investment Management Inc. (0.01%) and SG Americas Securities LLC. Insiders that own company stock include Frederic H Moll, Reza Zadno, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq, Alaleh Nouri and Global Investors Lp Viking.
View institutional ownership trends
.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRCT) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners